The druggable genome
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
An assessment of the number of molecular targets that represent an opportunity for therapeutic intervention is crucial to the development of post-genomic research strategies within the pharmaceutical industry. Now that we know the size of the human genome, it is interesting to consider just how many molecular targets this opportunity represents. We start from the position that we understand the properties that are required for a good drug, and therefore must be able to understand what makes a good drug target.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The dataset adds high-quality structural models across a broad range of Gene Ontology (GO) terms36,37, including pharmaceutically relevant classes such as enzymes and membrane proteins38 (Fig. 1d).”
From Highly accurate protein structure prediction for the human proteome (2021) · cites this paper as [38]
In the citing paper
“Proteins have several additional advantages as they are most often the direct mediators of biological processes and form the vast majority of currently druggable targets in disease160.”
From Measuring biological age using omics data (2022) · cites this paper as [160]
In the citing paper
“Only around 20% of the human proteome is considered to be druggable with small-molecule antagonists.”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [2]
In the citing paper
“Although this has been a highly effective approach, it has left potential drug targets undrugged or underdrugged45.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [45]
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Drug Discovery: A Historical Perspective
Drews, J. (2000) · Science · doi:10.1126/science.287.5460.1960 · Cited by 2,760 · cited 1×
“identified 483 targets, and concluded that there could be 5,000–10,000 potential targets on the basis of an estimate of the number of disease-related gene”
BackgroundMetabolite profiling for plant functional genomics
Fiehn, O., Kopka, J., Dörmann, P., Altmann, T., Trethewey, R. N., & Willmitzer, L. (2000) · Nature Biotechnology · doi:10.1038/81137 · Cited by 2,127 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundComparative Genomics of the Eukaryotes
Rubin, G. M., Yandell, M. D., Wortman, J. R., Gabor, G. L., Miklos, Nelson, C. R., Hariharan, I. K., Fortini, M. E., Li, P. W., Apweiler, R., et al. (2000) · Science · doi:10.1126/science.287.5461.2204 · Cited by 1,698
Apweiler, R. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.37 · Cited by 1,079
A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations
Raamsdonk, L. M., Teusink, B., Broadhurst, D., Zhang, N., Hayes, A., Walsh, M. C., Berden, J. A., Brindle, K. M., Kell, D. B., Rowland, J. J., et al. (2001) · Nature Biotechnology · doi:10.1038/83496 · Cited by 1,005 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
BackgroundTweeddale, H., Notley-McRobb, L., & Ferenci, T. (1998) · Journal of Bacteriology · doi:10.1128/jb.180.19.5109-5116.1998 · Cited by 393 · cited 1×
“One route to target discovery might therefore lie in identifying enzymes and receptors from metabolomic profilin”
Background
Cited by
Items 101–200 of 1,029
Protein Binding Pocket Dynamics
Stank, A., Kokh, D. B., Fuller, J. C., & Wade, R. C. (2016) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00516 · Cited by 445
Cornerstones of CRISPR–Cas in drug discovery and therapy
Fellmann, C., Gowen, B. G., Lin, P.-C., Doudna, J. A., & Corn, J. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.238 · Cited by 443
Ligand and Target Discovery by Fragment-Based Screening in Human Cells
Parker, C. G., Galmozzi, A., Wang, Y., Correia, B. E., Sasaki, K., Joslyn, C. M., Kim, A. S., Cavallaro, C. L., Lawrence, R. M., Johnson, S. R., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.029 · Cited by 439
Phenotypic screens as a renewed approach for drug discovery
Zheng, W., Thorne, N., & McKew, J. C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.001 · Cited by 423
Stapled Peptides for Intracellular Drug Targets
Verdine, G. L., & Hilinski, G. J. (2012) · Methods in Enzymology · doi:10.1016/b978-0-12-396962-0.00001-x · Cited by 433
Similarity-based machine learning methods for predicting drug–target interactions: a brief review
Ding, H., Takigawa, I., Mamitsuka, H., & Zhu, S. (2014) · Briefings in Bioinformatics · doi:10.1093/bib/bbt056 · Cited by 427
“Drugs have specific impacts on multiple proteins called targets by changing pharmaceutical functions of the targets [7], such as enzymes, ion channels, G protein-coupled receptors (GPCRs) and nuclear receptors.”
BackgroundTargeted Protein Degradation: from Chemical Biology to Drug Discovery
Cromm, P. M., & Crews, C. M. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.05.024 · Cited by 412
“…accessible, and are unable to target whole classes of proteins known to play key roles in disease, e.g. transcription factors, scaffolding proteins or nonenzymatic proteins inside the cell (Hopkins and Groom, 2002; Wells and McClendon, 2007; Surade and Blundell, 2012; Lazo and Sharlow, 2016).”
BackgroundTarFisDock: a web server for identifying drug targets with docking approach
Li, H., Gao, Z., Kang, L., Zhang, H., Yang, K., Yu, K., Luo, X., Zhu, W., Chen, K., Shen, J., et al. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl114 · Cited by 420
“However, identification and validation of druggable targets from amongst thousands of candidate macromolecules is still a challenging task (12,13).”
BackgroundInhibitors of Protein Tyrosine Phosphatases: Next‐Generation Drugs?
Bialy, L., & Waldmann, H. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461517 · Cited by 420
Edmondson, S. D., Yang, B., & Fallan, C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.04.030 · Cited by 422
The druggable genome: an update
Russ, A. P., & Lampel, S. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03666-4 · Cited by 424
Kinase mutations in human disease: interpreting genotype–phenotype relationships
Lahiry, P., Torkamani, A., Schork, N. J., & Hegele, R. A. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2707 · Cited by 420
“Because kinases comprise ∼20% of all putative drug target”
BackgroundDGIdb 2.0: mining clinically relevant drug–gene interactions
Wagner, A. H., Coffman, A. C., Ainscough, B. J., Spies, N. C., Skidmore, Z. L., Campbell, K. M., Krysiak, K., Pan, D., McMichael, J. F., Eldred, J. M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1165 · Cited by 413
“These categories for the most part were defined by the original seminal paper by Hopkins and Groom (12) who first defined the ‘druggable genome’ as genes belonging to over 130 specific biological types (kinases, nuclear hormone receptors, etc.”
BackgroundVillar, E. A., Beglov, D., Chennamadhavuni, S., Porco, J. A., Kozakov, D., Vajda, S., & Whitty, A. (2014) · Nature Chemical Biology · doi:10.1038/nchembio.1584 · Cited by 400
“The interaction of the ligands with their respective proteins was assessed in two ways: (1) solvent accessible surface area (SASA) analysis and (2) determination of contact atoms.”
Kindrachuk, J., Ork, B., Hart, B. J., Mazur, S., Holbrook, M. R., Frieman, M. B., Traynor, D., Johnson, R. F., Dyall, J., Kuhn, J. H., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03659-14 · Cited by 407
“Previously, we demonstrated the utility of species-specific kinome analysis with peptide kinome arrays for characterizing the modulation of host cell signaling networks, including responses to infection (25, 26).”
BackgroundBiochemical mechanisms of drug action: what does it take for success?
Swinney, D. C. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1500 · Cited by 394
“The majority of drug antagonists and inhibitors achieve their potency by competing with endogenous ligands or substrates at structurally defined binding site”
BackgroundKnockouts model the 100 best-selling drugs—will they model the next 100?
Zambrowicz, B. P., & Sands, A. T. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd987 · Cited by 393
“A recent review identified only 120 targets for all marketed drug”
BackgroundOuter membrane vesicles as platform vaccine technology
van der Pol, L., Stork, M., & van der Ley, P. (2015) · Biotechnology Journal · doi:10.1002/biot.201400395 · Cited by 378
“There is increasing interest in vesicles and recruitment of the immune system for medical applications which could be linked to the finding that 60% of the available pharmaceutical drugs exert their effect through interaction with membrane proteins [7].”
BackgroundRNA interference: From gene silencing to gene-specific therapeutics
Leung, R. K. M., & Whittaker, P. A. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.03.004 · Cited by 382
“The identification of most of the genes in the human genome has spawned varying estimates of the number of potential new drug targets that await discovery (Drews, 2000; Hopkins & Groom, 2002).”
BackgroundA General Chemical Method to Regulate Protein Stability in the Mammalian Central Nervous System
Iwamoto, M., Björklund, T., Lundberg, C., Kirik, D., & Wandless, T. J. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.07.009 · Cited by 386
Classification of scaffold-hopping approaches
Sun, H., Tawa, G., & Wallqvist, A. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2011.10.024 · Cited by 375
“Actually, due to the limited number of druggable targets [1,2], a large fraction of therapeutically interesting targets are not new and exploration of novel chemistries for these targets could be based on known ligands or ligand-protein complex structures.”
BackgroundViolin, J. D., DeWire, S. M., Yamashita, D., Rominger, D. H., Nguyen, L., Schiller, K., Whalen, E. J., Gowen, M., & Lark, M. W. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.173005 · Cited by 370
“These strategies have successfully targeted dozens of GPCRs in the discovery of new therapeutic agents (Hopkins and Groom, 2002).”
BackgroundVPAC and PAC receptors: From ligands to function
Dickson, L., & Finlayson, K. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.11.006 · Cited by 379
“GPCRs are heptahelicalmembrane proteins that have beendescribed as the ‘most important set of targets for research aimed at the design of new medicines' (Horn et al., 1998), and account for 30–45% of modern drug targets (Drews, 2000; Hopkins & Groom, 2002).”
BackgroundProtein-ligand interaction prediction: an improved chemogenomics approach
Jacob, L., & Vert, J.-P. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn409 · Cited by 378
“In particular, several classes of proteins such as G-protein-coupled receptors (GPCR), enzymes and ion channels represent a large fraction of current drug targets and important targets for new drug development (Hopkins and Groom, 2002).”
BackgroundUnexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.14 · Cited by 378
Kramer, J. A., Sagartz, J. E., & Morris, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2378 · Cited by 372
“This approach will generate knockout mouse models for the genes that represent the 'druggable genome”
BackgroundPubChem as a public resource for drug discovery
Li, Q., Cheng, T., Wang, Y., & Bryant, S. H. (2010) · Drug Discovery Today · doi:10.1016/j.drudis.2010.10.003 · Cited by 365
“Tremendous efforts have been made in the past decades by pharmaceutical industries and biotechnology companies that focus on the druggable genome [5,6] to identify novel drug targets for drug discovery.”
BackgroundVerdine, G. L., & Walensky, L. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2184 · Cited by 361
An overview of PROTACs: a promising drug discovery paradigm
Liu, Z., Hu, M., Yang, Y., Du, C., Zhou, H., Liu, C., Chen, Y., Fan, L., Ma, H., Gong, Y., et al. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00112-0 · Cited by 344
“However, some proteins lack bindable sites or enzymatic activity sites, like transcription factors, RAS family proteins [18], scaffolding proteins and regulatory proteins [19], making them insensitive to traditional small molecule drugs.”
BackgroundThe 7 TM G‐Protein‐Coupled Receptor Target Family
Jacoby, E., Bouhelal, R., Gerspacher, M., & Seuwen, K. (2006) · ChemMedChem · doi:10.1002/cmdc.200600134 · Cited by 359
Addiction to protein kinase CK2: A common denominator of diverse cancer cells?
Ruzzene, M., & Pinna, L. A. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.07.018 · Cited by 352
Peptide therapeutics: Targeting the undruggable space
Tsomaia, N. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.01.014 · Cited by 348
Chemogenomics: an emerging strategy for rapid target and drug discovery
Bredel, M., & Jacoby, E. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1317 · Cited by 356
“jpg" NDATA ITEM> ]> Over the past five decades, pharmacological compounds have been identified that collectively target the products of ∼400–500 genes in the human body; however, only ∼120 of these genes have reached the market as the targets of drug”
BackgroundChemical modulators of autophagy as biological probes and potential therapeutics
Fleming, A., Noda, T., Yoshimori, T., & Rubinsztein, D. C. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.500 · Cited by 349
“Indeed, it is estimated that the human genome contains approximately 3,000 'druggable' genes—that is, genes that encode proteins that are able to bind drug-like molecule”
BackgroundNIH Molecular Libraries Initiative
Austin, C. P., Brady, L. S., Insel, T. R., & Collins, F. S. (2004) · Science · doi:10.1126/science.1105511 · Cited by 348
Drug research: myths, hype and reality
Kubinyi, H. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1156 · Cited by 348
How Beyond Rule of 5 Drugs and Clinical Candidates Bind to Their Targets
Doak, B. C., Zheng, J., Dobritzsch, D., & Kihlberg, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01286 · Cited by 335
The Thermodynamics of Protein–Ligand Interaction and Solvation: Insights for Ligand Design
Olsson, T. S. G., Williams, M. A., Pitt, W. R., & Ladbury, J. E. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.09.073 · Cited by 334
Mechanism Matters: A Taxonomy of Cell Penetrating Peptides
Kauffman, W. B., Fuselier, T., He, J., & Wimley, W. C. (2015) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.10.004 · Cited by 333
“For example, the cytosolic delivery of bioactive peptides is becoming an especially important problem to solve in the rapidly developing field of inhibitors of protein-protein interactions in cells, which some authors have suggested will be the next great transformation in drug development[92,93].”
BackgroundLindsay, M. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1202 · Cited by 332
Keynote review: Structural biology and drug discovery
Congreve, M., Murray, C. W., & Blundell, T. L. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03484-7 · Cited by 338
Schmidtke, P., & Barril, X. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100574m · Cited by 331
Heteroaromatic Rings of the Future
Pitt, W. R., Parry, D. M., Perry, B. G., & Groom, C. R. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801513z · Cited by 332
Self-citationDNA sequencing: bench to bedside and beyond
Hutchison, C. A. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm688 · Cited by 297
“Genome sequences have provided potential targets for drug therapy (88,89) as well as vaccine candidates (90,91).”
BackgroundKang, L., Chung, B. G., Langer, R., & Khademhosseini, A. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.003 · Cited by 325
“Of these candidate targets, polysaccharides, lipids and nucleic acids are investigated less frequently than proteins, because of a lack of understanding of the involvement of these molecules in disease and a lack of small-molecule therapeutic agents [10, 11 ].”
BackgroundKatada, S., Hirokawa, T., Oka, Y., Suwa, M., & Touhara, K. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.4723-04.2005 · Cited by 322
“Because the GPCR families are major targets of therapeutic agents ( Hopkins and Groom , 2002 ) , many studies have focused on the molecular ba - sis by which they bind agonists .”
BackgroundProperties and identification of human protein drug targets
Bakheet, T. M., & Doig, A. J. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp002 · Cited by 324
“Hopkins and Groom (Hopkins and Groom, 2002) identified 120 successful proteins as rule-of-five compliant, oral drug targets for approved drugs, using sequence motifs, where the two largest molecular target classes were GPCRs and enzymes.”
BackgroundInfluentialRemoving Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models
Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., & Steckler, T. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.173 · Cited by 328
“This reductionist approach has been encouraged also by the explosion of the genomic and proteomic technologies that opened up new areas of discoveries in biomedical sciences (Drews and Ryser, 1997; Hopkins and Groom, 2002; Imming et al, 2006).”
Binding MOAD (Mother Of All Databases)
Hu, L., Benson, M. L., Smith, R. D., Lerner, M. G., & Carlson, H. A. (2005) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20512 · Cited by 328
“Smaller molecules would tend to provide better oral absorption and fewer functional groups for toxicity concerns.[139, 122, 140, 141] Of course, ligand efficiencies reflect “bindability”, and it is important to recognize that there are additional properties that make a protein a suitable drug target.”
BackgroundProteomics of Integral Membrane ProteinsTheory and Application
Speers, A. E., & Wu, C. C. (2007) · Chemical Reviews · doi:10.1021/cr068286z · Cited by 325
Suthram, S., Dudley, J. T., Chiang, A. P., Chen, R., Hastie, T. J., & Butte, A. J. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000662 · Cited by 322
“Most existing drug target genes usually fall into a comparatively small set of gene families such as G protein coupled receptors, serine proteases etc [26].”
BackgroundThe genome of the hydatid tapeworm Echinococcus granulosus
Zheng, H., Zhang, W., Zhang, L., Zhang, Z., Li, J., Lu, G., Zhu, Y., Wang, Y., Huang, Y., Liu, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2757 · Cited by 319
Analyzing the Topology of Active Sites: On the Prediction of Pockets and Subpockets
Volkamer, A., Griewel, A., Grombacher, T., & Rarey, M. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100241y · Cited by 300
Multipass membrane protein structure prediction using Rosetta
Yarov‐Yarovoy, V., Schonbrun, J., & Baker, D. (2006) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.20817 · Cited by 323
“The biological significance of the helical TM proteins is highlighted by the fact that 50% of current drugs in use target membrane proteins.(1) Helical TM proteins are predicted to encode 20–30% of all open reading frames of known genomes; however, currently, all types of membrane proteins represent only about 0.”
Zhu, T., Cao, S., Su, P.-C., Patel, R., Shah, D., Chokshi, H. B., Szukala, R., Johnson, M. E., & Hevener, K. E. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301916b · Cited by 313
Utility of homology models in the drug discovery process
Hillisch, A., Pineda, L. F., & Hilgenfeld, R. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03196-4 · Cited by 310
“Based on the total numbers of known genes, disease-modifying genes and drugable proteins, the number of drug target proteins, for humans, has been estimated at ~600–1500 [18].”
BackgroundChemistries of bifunctional PROTAC degraders
Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313
Duncan, J. S., & Litchfield, D. W. (2008) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2007.08.017 · Cited by 304
Genomic-scale prioritization of drug targets: the TDR Targets database
Agüero, F., Al-Lazikani, B., Aslett, M., Berriman, M., Buckner, F. S., Campbell, R. K., Carmona, S., Carruthers, I. M., Chan, A. W. E., Chen, F., et al. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2684 · Cited by 306
Self-citationChemokine receptor antagonists: overcoming developmental hurdles
Horuk, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2734 · Cited by 303
“GPCRs have become one of the most important drug targets for the pharmaceutical industry, with more than 30% of all US marketed therapeutics acting on the”
BackgroundMembrane proteins and membrane proteomics
Tan, S., Tan, H. T., & Chung, M. C. M. (2008) · PROTEOMICS · doi:10.1002/pmic.200800597 · Cited by 279
“This subset of proteins actually represents 60% of the known existing and future drug targets [6].”
Systems biology in cardiovascular disease: a multiomics approach
Joshi, A., Rienks, M., Theofilatos, K., & Mayr, M. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00477-1 · Cited by 301
A practical view of ‘druggability’
Keller, T. H., Pichota, A., & Yin, Z. (2006) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2006.06.014 · Cited by 295
“It provides an interesting counterpoint to the Hopkins and Groom [5 ] arguments about protein druggability.”
BackgroundInfluentialErratum: Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.52 · Cited by 311
sc-PDB: a 3D-database of ligandable binding sites—10 years on
Desaphy, J., Bret, G., Rognan, D., & Kellenberger, E. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku928 · Cited by 300
“The concept of ligandability has thus been suggested to qualify the ability of a protein to bind with high affinity a small molecular weight compound (4,5).”
BackgroundProbing the Probes: Fitness Factors For Small Molecule Tools
Workman, P., & Collins, I. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.05.013 · Cited by 299
Cell permeability beyond the rule of 5
Matsson, P., Doak, B. C., Over, B., & Kihlberg, J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.03.013 · Cited by 297
Role of cholesterol in the function and organization of G-protein coupled receptors
Pucadyil, T. J., & Chattopadhyay, A. (2006) · Progress in Lipid Research · doi:10.1016/j.plipres.2006.02.002 · Cited by 296
“Importantly, 30– 50% of clinically administered drugs act as either agonists or antagonists at GPCRs with several ligands of GPCRs among the top 100 globally selling drugs thus pointing out their immense therapeutic potential [161,162].”
BackgroundSmith, M. C., & Gestwicki, J. E. (2012) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2012.10 · Cited by 286
Small-Molecule Modulation of Protein Homeostasis
Burslem, G. M., & Crews, C. M. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00077 · Cited by 283
Modulators of 14-3-3 Protein–Protein Interactions
Stevers, L. M., Sijbesma, E., Botta, M., MacKintosh, C., Obsil, T., Landrieu, I., Cau, Y., Wilson, A. J., Karawajczyk, A., Eickhoff, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00574 · Cited by 279
Predicting protein druggability
Hajduk, P. J., Huth, J. R., & Tse, C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03624-x · Cited by 289
PDTD: a web-accessible protein database for drug target identification
Gao, Z., Li, H., Zhang, H., Liu, X., Kang, L., Luo, X., Zhu, W., Chen, K., Wang, X., & Jiang, H. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-104 · Cited by 288
“It has been estimated that there are more than 2,000 potential drug targets with at least one drug candidate in clinical trial [2,3].”
BackgroundAssessing drug-likeness – what are we missing?
Vistoli, G., Pedretti, A., & Testa, B. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.11.007 · Cited by 278
Franzén, O., Jerlström-Hultqvist, J., Castro, E., Sherwood, E., Ankarklev, J., Reiner, D. S., Palm, D., Andersson, J. O., Andersson, B., & Svärd, S. G. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000560 · Cited by 232
“Groom [47], all these genes are also found in the GS genome.”
BackgroundDiscovery of tissue-specific exons using comprehensive human exon microarrays
Clark, T. A., Schweitzer, A. C., Chen, T. X., Staples, M. K., Lu, G., Wang, H., Williams, A., & Blume, J. E. (2007) · Genome Biology · doi:10.1186/gb-2007-8-4-r64 · Cited by 280
“Nearly all small-molecule drug targets fall into 130 InterPro domain protein families [48]; 3,365 genes (transcript clusters) containing one of these protein domains were identified.”
BackgroundDiversity-oriented synthesis; a spectrum of approaches and results
Spandl, R. J., Bender, A., & Spring, D. R. (2008) · Organic & Biomolecular Chemistry · doi:10.1039/b719372f · Cited by 281
Druggability Analysis and Structural Classification of Bromodomain Acetyl-lysine Binding Sites
Vidler, L. R., Brown, N., Knapp, S., & Hoelder, S. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300346w · Cited by 278
Cimermancic, P., Weinkam, P., Rettenmaier, T. J., Bichmann, L., Keedy, D. A., Woldeyes, R. A., Schneidman-Duhovny, D., Demerdash, O. N., Mitchell, J. C., Wells, J. A., et al. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.01.029 · Cited by 268
“have pockets larger than 250 Å(3) (many of which may not be druggable) and could potentially be subjected to ligand discovery based on binding pocket knowledge [16,17].”
BackgroundRask-Andersen, M., Masuram, S., & Schiöth, H. B. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135943 · Cited by 282
Booth, B., & Zemmel, R. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1384 · Cited by 278
Can cell systems biology rescue drug discovery?
Butcher, E. C. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1754 · Cited by 276
“Even more worrisome is the rate of approval of drugs against new targets (molecules not the targets of previous drugs): over the past decade, the entire industry has averaged only two to three small-molecule drugs against such 'innovative' targets per yea”
BackgroundMultivalent Small-Molecule Pan-RAS Inhibitors
Welsch, M. E., Kaplan, A., Chambers, J. M., Stokes, M. E., Bos, P. H., Zask, A., Zhang, Y., Sanchez-Martin, M., Badgley, M. A., Huang, C. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.006 · Cited by 274
Pharos: collating protein information to shed light on the druggable genome
Nguyen, D.-T., Mathias, S., Bologa, C., Brunak, S., Fernandez, N., Gaulton, A., Hersey, A., Holmes, J., Jensen, L. J., Karlsson, A., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1072 · Cited by 279
“targets have an FDA approved drug (1).”
Bowman, G. R., & Geissler, P. L. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209309109 · Cited by 279
“MIðX; Y Þ 1⁄4 ∑ x∈x ∑ y∈y pðx; yÞ log pðx; yÞ pðxÞpðyÞ [1] Fig.”
Cytoplasmic destruction of p53 by the endoplasmic reticulum‐resident ubiquitin ligase ‘Synoviolin’
Yamasaki, S., Yagishita, N., Sasaki, T., Nakazawa, M., Kato, Y., Yamadera, T., Bae, E., Toriyama, S., Ikeda, R., Zhang, L., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601490 · Cited by 275
“, cytoplasmic localization and enzymatic activity (Hopkins and Groom, 2002).”
BackgroundRamsay, R., & Tipton, K. (2017) · Molecules · doi:10.3390/molecules22071192 · Cited by 258
“Even with the increase in the use of drugs for receptors to modulate signals from outside the cell, 47% of all current drugs inhibit enzyme targets [1].”
BackgroundSchneider, M., Radoux, C. J., Hercules, A., Ochoa, D., Dunham, I., Zalmas, L.-P., Hessler, G., Ruf, S., Shanmugasundaram, V., Hann, M. M., et al. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00245-x · Cited by 273
Yang, H., Qin, C., Li, Y. H., Tao, L., Zhou, J., Yu, C. Y., Xu, F., Chen, Z., Zhu, F., & Chen, Y. Z. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1230 · Cited by 270
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271
Drug discovery with engineered zinc-finger proteins
Jamieson, A. C., Miller, J. C., & Pabo, C. O. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1087 · Cited by 266
“The completion of the human genome project has identified more than 30,000 human genes, and thousands of these may represent potential new drug target”
BackgroundStrategies for Improving Peptide Stability and Delivery
Al Musaimi, O., Lombardi, L., Williams, D. R., & Albericio, F. (2022) · Pharmaceuticals · doi:10.3390/ph15101283 · Cited by 249
“For instance, while the large molecules are incapable of penetrating cells, the hydrophobic interaction is devoid with small molecules [8].”
BackgroundData completeness—the Achilles heel of drug-target networks
Mestres, J., Gregori-Puigjané, E., Valverde, S., & Solé, R. V. (2008) · Nature Biotechnology · doi:10.1038/nbt0908-983 · Cited by 265
Getting pharmaceutical R&D back on target
Bunnage, M. E. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.581 · Cited by 258
Dhakal, A., McKay, C., Tanner, J. J., & Cheng, J. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab476 · Cited by 256
“In fact, the binding site is considered druggable if the ligand binds with high affinity at the binding site and has an effective therapeutic action [9].”
Pathway Mapping Tools for Analysis of High Content Data
Ekins, S., Nikolsky, Y., Bugrim, A., Kirillov, E., & Nikolskaya, T. (2006) · High Content Screening · doi:10.1385/1-59745-217-3:319 · Cited by 255
Masuho, I., Ostrovskaya, O., Kramer, G. M., Jones, C. D., Xie, K., & Martemyanov, K. A. (2015) · Science Signaling · doi:10.1126/scisignal.aab4068 · Cited by 265
“As such,GPCRs are among the most successful and tractable drug targets, and they account for about 30 to 40% of the medications currently on the market (6, 7).”
BackgroundCell-division inhibitors: new insights for future antibiotics
Lock, R. L., & Harry, E. J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2510 · Cited by 263
“Some bacterial cell-division proteins, including the tubulin-like FtsZ and the predicted ATP-binding cassette (ABC) transporter FtsE, contain identifiable druggable domains that bind GTP and ATP, respectivel”
BackgroundEngineering GPCR signaling pathways with RASSLs
Conklin, B. R., Hsiao, E. C., Claeysen, S., Dumuis, A., Srinivasan, S., Forsayeth, J. R., Guettier, J.-M., Chang, W. C., Pei, Y., McCarthy, K. D., et al. (2008) · Nature Methods · doi:10.1038/nmeth.1232 · Cited by 254
“GPCRs are also the largest gene family targeted for drug discover”
BackgroundCunningham, J. T., Moreno, M. V., Lodi, A., Ronen, S. M., & Ruggero, D. (2014) · Cell · doi:10.1016/j.cell.2014.03.052 · Cited by 260
Metadata
- Authors
- Hopkins, A. L., & Groom, C. R.
- Affiliations
- Pfizer (United Kingdom) (GB)
- Corresponding author
- Groom, Colin R.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-09
- Volume
- 1
- Issue
- 9
- Pages
- 727-730
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2074370114
- Cited by
- 3,305
- References
- 16
- Citations by year
- 2026: 91 · 2025: 113 · 2024: 131 · 2023: 116 · 2022: 155 · 2021: 150 · 2020: 144 · 2019: 147 · 2018: 136 · 2017: 132 · 2016: 144 · 2015: 182 · 2014: 162 · 2013: 161 · 2012: 212
- FWCI
- 70.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Science, Research, and Medicine
- Keywords
- druggable genome, therapeutic target, molecular targets, target identification
- MeSH terms
- Biological Availability, Chemistry, Pharmaceutical, Humans, Molecular Biology, Pharmacokinetics, Genome, Human
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.